Dr Tisman's Curriculum Vitae

GLENN TISMAN, M.D.

Licensure:

California  Active

Board Certification

Certified by the National Board of Medical Examiners 1969

Board Certified Internal Medicine

Board Certified Medical Oncology

EDUCATION

Hofstra University: Hempstead, Long Island, New York, Bachelor of Arts, June1965

State University of New York at Buffalo School of Medicine- Buffalo, New York Medical Doctor, June1969

PUBLICATIONS

LETTERS

Tisman, G.:  “Intravascular Coagulation and Hyaline-Membrane Disease.” Lancet 2:357, 1968

Tisman, G.:  “Dilantin and Folic Acid.” Ann. Int. Med. 70:233-234, 1969

Tisman, G.:  “Uremia and Kanamycin.” New Eng. J. Med. 281:851, 1969

Tisman, G.: “Phenytoin, Conjugases and Folate Depletion.” Lancet 2:800, 1970

Tisman, G.: “Bicarbonate and Cerebral Blood Flow.” Lancet 1:189-190, 1970

Tisman, G.,  Winston, W. A. : “Methotrexate Impurities.” Lancet 1:1178, 1970

Tisman, G.: “Diagnostic Value of Serum Folate Level.” New Eng. J. Med. 287:446-447, 1972

Tisman, G., Wu, S. G. and Safire, G. E.: “Intralesional PPD in Malignant Melanoma.” Lancet 1:7899, 1975

Tisman, G., Wu, S. G. and Rodriquez, E.: “The Methylfolate-Trap Hypothesis.” Lancet 1:184, 1975

Tisman, G., Wu, S. G., Safire, G.: “Intralesional PPD for Therapy in Malignant Melanoma.” Lancet 1:161, 1975

Tisman, G., Wu, S. G.: “Oestrogen-Binding Protein in Blood to Predict Response of Breast Cancer to Hormone Manipulation.” Lancet 11:145-146, 1976

Tisman, G., Wu, S. G.: “High Affinity Estrogen-binding Protein.” Lancet 1:39, 1977

Tisman, G., Wu, S. G.: “Lithium-Induced Granulocytosis.” Lancet 1:251-252, 1977

Tisman, G., Wu, S. G.: “Allopurinol Modulation of High-Dose Fluorouracil Toxicity.” Lancet 1:8130, 1979

ABSTRACTS:

Tisman, G., Herbert, V.: “Inhibition by Penicillamine of DNA Synthesis of Human Bone Marrow

In Vitro.” Fed. Proc. 30:518, 1971.

Tisman, G., Peisach, J., Herbert, V.: “Iron Chelation by Penicillamine.” J. Clin. Invest. 50:93A, 1971.

Tisman, G., Herbert, V.: “Evidence for a Serum Factor Enhancing Incorporation of 3HTdR (3H Thymidine)   into DNA-Thymine (DNA-T) of Human Bone Marrow Cells. Clin. Red. 19:433, 1971

Tisman, G., Herbert, V.: “Inhibition by Human Serum, Dilantin (Diphenylhydantoin) and Methotrexate (MTX) and Enhancement by 2-Deoxy-glucose of 3H-Pteroylgutamic Acid (3HPGA) and 3H-5-Methyltetradrofolate (M-THF) Uptake by Human Bone Marrow Cells In Vitro” Clin. Res. 19:433, 1971.

Tisman, G., Herbert, V., Go, L. T., Brenner, L.: “In Vitro Demonstration of Immunosuppression Without Bone Marrow Suppression by Alcohol and Bleomycin.” Clin. Res. 19:730, 1971.

Herbert, V., Tisman, G., Go, L. T., Brenner, L.: “Determination of Therapeutic Index of Drugs by In Vitro  Sensitivity Test Using Human Host and Tumor Cell Suspensions.” Clin. Res. 19:738, 1971.

Herbert, V., Tisman, G., Go, L. T., Brenner, L.: “B12 Dependence of Cell Uptake of Serum Folate and Cell Folate Depletion in B12 Deficiency.” Clin. Res. 20:489, 1972.

Herbert, V., Tisman, G., Go, L. T., Brenner, L.: “Test for Megaloblasiosis: The dUSuppression Test Using 125 IUdR.” Clin. Res. 20:490, 1972.

Tisman, G., Herbert, V., Go, L. T., Brenner, L.: “Human Serum Factor in Granulocyte DNA Regulation In Virto: Relation to Colony Stimulation Factor.” Clin. Res. 20:503, 1972.

Tisman, G., Herbert V., Go, L. T., Brenner, L.: “Effects on Human Bone Marrow of Cyclic AMP (CAMP), Theophyllinc and Prostaglandin (PGEI).” Clin. Res. 20:503, 1972.

Tisman, G., Herbert V, Edlis, H., Go, L. T., Brenner, L.: “Difference in DNA Metabolism in Tumor vs. Host Cells: Predicting Patient Response to Chemotherapy.” J. Clin. 51:98A, 1972.

Tisman, G., Herbert V., Go, L.T., Brenner, L.: “Alcohol and Infection: The Suppression by Ethanol of Human Myelopoiesis.” Amer. J. Clin. Nutr. 15:460, 1972.

Tisman, G., Engelberg, M., Bateman, J.: “Lymphocyte Immunoglobulin (Ig) Receptors and Mitogen Responsiveness: Aids in Determining Early Stage Lymphoproliferative Disease and Therapy.” Clin. Res. 21, 1972.

Tisman, G., Bateman, J., Marshall, G. J.: “Aggressive Immunocytoma-B Type: Possible Relation to Steroid Treated Autoimmune Disease.” American Soc. of Hematology Meeting Program. 347:149, 1972.

Tisman, G., Herbert, V.: “Selective Kill of Lymphocyte Subpopulations by Varying Concentrations of Immunosuppressive Drugs.” American Soc. of Hematology Program 100:66, 1972

Tisman, G., Herbert, V.: “Effect of Lithium on Granulopoiesis.” American Soc. of Hematology Program. 233:111, 1972.

Tisman, G., Safire, G., Wu, S. G.: “Lithium Carbonate Stimulation Test in Blood Disorders.” Clin. Res. 23:103A, 1975.

Tisman, G., Safire, G., Wu, S. G.: “Lithium Carbonate Protection Against Cancer Chemotherapy Induced Leukopenia.” Clin. Res. 23:115A, 1975.

Tisman, G., Wu. S. G., Safire, G., Rodriguez, E.: “Measurement of B12 Binders in Cancer Patients.” Clin. Res. 23:283A, 1975.

Tisman, G., Wu, S. G., Safire, G., Rodriguez, E.: “A Study ofIn Vivo B12 Binders.” Clin. Res. 23:284A, 1975.

Tisman, G., Wu, S. G.: “Intralesional PPD for Therapy in Malignant Melanoma.” Proceedings of the American Association for Cancer Research (AACR). 16:204, 1975.

Tisman, G., Wu, S.G., Safire, G., Rodriguez, E.: "Null Lymphocytosis." Clin. Res. 24:110A,

1976.

Tisman, G., Kellon, D.B., Wu, S.G., Safire, G.E.: 'Use of Tamoxifcn in Tumors Other Than

Breast Cancer." Clin. Res. 24:381A, 1976.

Tisman, G., Kellon, D.B., Wu, S.G., Safire, G.E.: "Failure of Lithium to Induce Leukocytosis in a Patient with Granulocytic Leukemia in Complete Remission.” Clin. Rcs. 24:322A, 1976.

Tisman, G., Wu, S.G.: "Inhibition of DNA Synthesis by Impurities in Commercial

Methotrexate.” Clin. Res. 24:550A, 1976.

Tisman, G., Hittle, T., Halley, J.: “Skin Inflammation Caused by Cancer Immunotherapy with Intradermal Connaught.  Tice and Glaxo BCG.”  Clin. Res. 25:412A, 1977.

Tisman, G., Wu, S.G., Hittle, T.: "Scrum Ferritin as a Parameter of Response to Cancer Chemotherapy."   Clin. Res. 24:580A, 1977.

Tisman, G., Wu, S.G., Hittle, T., Stevens, T., fox, M.: “Treatment of Metastatic colon Cancer with 5-FU,  MeCCNU, BCG and Leucovorin." Proceedings of the American Association for Cancer Research (AACR). 19:217A, 1978.

Tisman, G., Wu., S.G.: "High Dose 5-Flourouracil (5FU) Combination Chemotherapy for Refractory 

Malignancy." Clin.  Res.  27:54A, 1979.

Tisman, G., Wu, S.G.: 'Successful Salvage of Failures of Adjuvant Treated Breast Cancer with

Sequential High Dose Methotrexate and 5-Fluorouracil.” 2nd International Conference on the

Adjuvant Therapy of Cancer, Tucson, Arizona, 1979.

Tisman, G., Testa.  D.: “Not a Laughing Matter (Nitrous Oxide).” The Journal of the American 

Dental Association. 98:528, 1979.

Tisman, G., Isacoff, W.H., Drakes, T.: “Salvage of Breast Cancer Adjuvant Treatment Failures with High Dose Methotrexate and 5FU." Proceedings of the American Association for Cancer Research (AACR). 20:565, 1979.

Tisman, G., Wu, S.C., Strum, S.B. "Methotrexate Directed 5FU Incorporation into RNA of Tumor but NotNormal Bone Marrow Cells." Proceedings of the American Association for Cancer Research (AACR). 20:1061, 1979.

Tisman, G., Isacoff, W.H., Block, J.B.: “Treatment of Advanced Colorectal Carcinoma with High Dose Methotrexate (HD-MTX) Given Alone and in Combination with 5-Fluorouracil (5FU).” Proceedings of the American Society of Clinical Oncology (ASCO). 20:C-373, 1979.

Wu, S.G., Kosch, A., McNamee, L.J., Strum, S.B., Tisman, G.: “Short-Term Intra-Arterial Infusion of Cis-Platinum Diammine Dichloride (CPDD) for Regional Control of Cancer.” Proceedings of the American Society of Clinical Oncology (ASCO). 20:C-631, 1979.

Tisman, G., Kosch, A.: “Successful Control of Local Tumors with Intra-Arterial Infusions of Cis-Platinum Diammine Dichloride (CPDD). "The Western Association of Gynecologic Oncologists, Seventh Annual   Meeting, 1979.

Tisman, G., Wu, S.G.: “Evaluation of a Four Hour (Short-Term) and Long-Term (Clonogenic) In Vitro Assay for Murine L1210, Human Tumor and Human Bone Marrow Cell Sensitivity to Drugs. “Program Human Tumor Cloning, Agenda for Workshop on Human Tumor Cloning Methods, 1980.

Tisman, G., Wu, S.G.: “Evaluation of the Human Tumor Stem Cell Assay in the Clinical Practice of Oncology.” Proceedings of the American Association for Cancer Research (AACR). 21:139, 1980.

Tisman, G., Wu, S.G., Tisman, N.: “Evaluation of Human Tumor Cell Sensitivity to Both Low and High Concentrations of Methotrexate (MTX).” Clin. Res. 29:065A, 1981.

Tisman, G., Wu, S.G., Tisman, N.: “The Clinical and Laboratory Evaluation of a Modified Tumor Stem Cell Assay for the Determination of Human Tumor Cell Sensitivity.” Clin. Res. 29:065A, 1981.

Tisman, G., Wu, S.G.: “The ‘Clonogenic Cluster’: An Interesting Laboratory Observation.” Proceedings of the American Association for Cancer Research (AACR). 22:236, 1981.

Tisman, G., Wu, S.G.: “The Clinical and Laboratory Evaluation of a Modified Tumor Stem Cell Assay For The Determination of Human tumor Cell Drug Sensitivity.” Proceedings of the American Society of Clinical Oncology (ASCO). 22:364, 1981.

Tisman, G., Hsu, M.Y.K.: “Clonogenic Clusters in Clonogenic Assays for Predictions of Chemotherapy Sensitivity.” Third Conference on Human Tumor Cloning, Tucson, Arizona, 1982.

Tisman, G., Neuman, D.: “Attempts to Quality Control and Standardize the Human Tumor Stem Cell Assay (HTSCA).” Third Conference on Human Tumor Cloning, Tucson, Arizona, 1982.

Tisman, G., Neuman, D.: “Attempts to Quality Control and Standardize the Human tumor Cell Assay (HTSCA).” Clin. Res. 30:070A, 1982.

Hsu, M.Y.K., Tisman, G., Neuman, D., Joseph, R.: “HTSCA in Cancer Chemotherapy Planing.” Proceedings of the American Society of Clinical Oncology (ASCO). 1:30, 1982.

Tisman, G., Neuman, D., Hsu, M.Y.K.: “Continued Studies With a Modified Clonogenic Assay.” Proceedings of the American Society of Clinical Oncology (ASCO). 1:31, 1982.

Neuman, D., Tisman, G., Dine, M.: “Attempts to Quality Control and Standardize the Human Tumor Stem Cell Assay (HTSCA).” Proceedings of the American Society of Clinical Oncology (ASCO). 1:31, 1982.

Tisman, G., Neuman, D., Hsu, M.Y.K.: “Studies of Clonal Heterogencity of Human Tumors in the Soft Agar Clonogenic Assay.” Proceedings of the American Association for Cancer Research (ARRCR). 23:139, 1982.

Tisman, G., Hsu, M.Y.K. and Neuman, D.: “The Human Tumor Stromal Cell Assay (HTSCA).” Clin. Res. 30:748A, 1982.

Tisman, G., Hsu, M.Y.K., Neuman, D.: “The Human Tumor Stromal Cell Assay: Confusion With the Human Tumor Stem Cell Assay.” Clin. Res. 30:748A, 1982.

Tisman, G., Hsu, M.Y.K., Neuman, D.: “Cis-Platunum Activity In Vitro Against Melanoma.” Proceedings of the American Society of Clinical Oncology (ASCO). 1983.

Tisman, G., Flener, V., Hsu, M.Y.K., Neuman, D., Buck, L., Tisman, N., Chakhmakhchian. H., Serena, D.: “Outpatient High Dose Cis-Platinum Continuous Infusion Chemotherapy.” Proceedings of the American Society of Clinical Oncology (ASCO). 3:27, 1984.

Tisman, G., Hsu, M.Y.K., Neuman, D., Buck, L., Tisman, N., Chakhmakhchian, H., Serena, D.: “Clonal Heterogeneity in Soft Agar Assay of Human Tumors.” Proceedings of the American Association for Cancer Research (AACR). 25:28, 1984.

Tisman, G., Flener, B., Jones, J., Buck, L.: “Possible Potentiation of Fluoropyrimidine Anti-Tumor Activity by Pteroylgutamic Acid (Folic Acid) and Cyanocobalamin (B12).” Clin. Res. 33:459A, 1985.

Tisman, G., Flener, V., Jones, M., Buck, L.: “Overcoming Colon Cancer Resistance to Hepatic Artery Infusional 5FUdR Chemotherapy with Folinic Acid.” Clin. Res. 33:459A, 1985.

Tisman, G., Flener, V., Jones, M., Buck, L.: “Continuous Subcutaneous Infusion of Cancer Chemotherapy for Ambulatory Patients.” Proceedings of the American Society of Clinical Oncology (ASCO). 4:47, 1985.

Tisman, G., Flener, V., Jones, M., Buck, L.: “Possible Enhancement of 5-Fluorouracil Clinical Activity by Large Doses of Pteroylglutamic Acid (Folic Acid).” Proceedings of the American Association for Cancer Research (AACR). 26:159, 1985.

Tisman, G., Flener, V., Jones, M.< Buck, L.: “Reestablishing Hepatic Tumor Arterial Perfusion with Urokinase.” Proceedings of the American Association for Cancer Research (AACR). 27:191, 1986.

Tisman, G., Flener, V., Jones, M., Buck, L., Tisman, N.: “Folic Acid and Leucovorin Modulation of 5FU Activity.” Proceedings of the American Society of Clinical Oncology (ASCO).5:37, 1986

Tisman, G., Nguyen, H., Buck, L.: “Development of Computer Software to Manage Chemotherapy Dosing and Evaluate Patient Response.” Proceedings of the American Society of Clinical Oncology (ASCO). 6:230, 1987.

Tisman, G., Flener. V., Jones, M., Buck, L.: “Sequential Methotrexate (MTX)-5FU-Leucovorin Plus Adriamycin-Cytoxan Alternating Chemotherapy as Adjuvant Chemotherapy for Breast Cancer.” Proceedings of the American Association for Cancer Research (AACR), 28:198, 1987.

Tisman, G., Van Antwerp, R.: “Treatment of the Myelodysplastic Syndrome of Refractory Anemia with Ringed Sideroblasts with Interferon 2 Alpha (Schering).” Proceeding of the American Society of Clinical Oncology (ASCO). 7:720, 1988.

Tisman, G.: “Intermediate Dose Thiotepa for Refractory Ovary Cancer.” Proceedings of the American Association for Cancer Research (AACR). Vol. 29:881, 1988.

Vu, T., Bateman, R., Flener, V., Tisman, G.: “The Parmacokinetic Parameters of High-Dose Leucovorin-FUdR I.V. Therapy Associated with Clinical Toxicity: Possible Modulation of 5-FUdR Pharmacokinetics by Leucovorin and Dipyridamole: Possible Enhanced Toxicity in B12 Deficiency.” Proceedings of the American Federation of Clinical Research. Vol. 37:862A, No. 3, 1989.

Tisman, G., Baca, L., Richards, S.: “Stressing the dU Suppression Test: An Easily Controlled Laboratory Model to Study Folate and B12 Metabolism of Human Immunocytes.” Clinical Research. Vol. 37:354A, No. 3, 1989.

Tisman, G., Vu, T., Bateman, R., Vanyo, L., Ramos, M: “Evaluation of a New, Sensitive, Peripheral Blood dU Suppression Test: Uncovering Occult Early Folate Deficiency.” Proceedings of the American Society of Hematology. Vol. 74:217A, No. 7, 1989.

Tisman, G., Vu, T., Bateman, R., Vanyo, L, Ramos, M.: “A Phase One Study of a New Anti B12 Therapy for Cancer Patients: Out-Patient Inhalation of N20; and a New Test to Monitor its Anti-B12 Activity: dU Suppression of Peripheral Blood Mononuclear Cells.” Proceedings of the American Society of Hematology. Vol. 74:306A, No. 7 1989.

Vanyo, L., Vu, T., Bateman, R., Conners, S., Tisman, G.: “New Laboratory Evidence Suggesting 5FUdR May Be A Better Chemotherapy than 5-FU When Modulated by Leucovorin.” American Society of Clinical Oncologist. Vol. 9:78, 1990.

Vu, T., Vanyo, L., Conners, S., Ramos, M., Tisman, G.: “Interactions Between Vitamin B12 and LiCl on Human Buffy Coat and L1210 Murine Leukemia Cells. Lithium is a Potent Modulator of Cellular Nucleotide Metabolism and Vitamin B12 Uptake.” In Press in The International Symposium on Present Status and Perspectives of Lithium in Biology and Medicine, European Academy, Nonwiler/Trier (Germany), 1990.

Vanyo, L., Vu, T., Amin, J., Conners, S., Ramos, M., Tisman, G.: “Lithium Enhancement of Vitamin B12 Transport in L1210 Murine Leukemia Cells.” Proceedings of the American Federation of Clinical Research, Vol. 38:775A, No. 3, 1990.

Vu, T., Vanyo, L., Conners, S., Amin, J., Ramos, M., Tisman, G.: “Hydroxocobalamin May Be A Potent Inhibitor of the de Novo Pathway of DNA Synthesis.” Proceedings of the American Society of Clinical Research, Vol. 38:777A, No. 3, 1990.

Tisman, G., Vu, T., Amin, J., Bateman, R., Vanyo, L.: “Measurement of B12 on Transcobalamin II (HoloTC II) Using Microfine Glass:  Significance of Evaluating B12 Absorption Following Chemotherapy.” Proceedings of the American Society of Hematology, Vol. 76:187A No. 10 Supp. 1, 1990.

Vu, T., Amin, J., Ramos, M., Tisman, G.: “A New and Rapid Test to Measure differing Transcobalamin II Proteins:  Significant Variations in Metastatic Liver Disease. A New Test to Quantitate Serum HoloTC II.” American Federation of Clinical Research. Vol. 39:32A, No. 1, 1990.

Tisman, G., Vu, T., Amin, J., Ramos, M., Flener, V.: “A new and Rapid Test to Measure B12 on Transcobalamin II Using Microfine Glass:  Use In Evaluating Metastatic Liver Disease and B12 Depletion Following Chemotherapy.” Proceedings of the American Association for Cancer Research, (AACR) Vol. 32:1220, 1991.

Tisman, G., Vu, T., Amin J., Flener, V., Ramos, M.: “Laboratory and Clinical Evidence that Large Concentrations of Hydroxocobalamin Inhibit Tumor Cell Growth.” Proceedings of the American Society of Clinical Oncology (ASCO), Vol. 10:330, 1991.

Tisman, G., Vu, T., Amin, J., Ramos, M., Vanyo, L.: “Cancer Patients are Frequently in Negative Vitamin B12 Balance and Exhibit hyperhomocysteinemia” Proceedings of the American Federation for Clinical Research (AFCR) Vol. 39:667A, No. 3, 1991.

Tisman, G., Vu, T., Amin, J., Flener, V., Ramos, M.: “Correlating Toxicity and Tumor Response of Continuous 5-FU Intravenous Infusions by Measuring Serum 5-FU and Homocysteine Levels in Cancer Patients.” Proceedings of the American Federation for Clinical Research (AFCR) Vol. 39:668A, No. 3, 1991.

Tisman, G., Vu, T., Amin, J., Vanyo, L., Flener, V., Ramos, M.: “Measurement of Serum Homocysteine Levels Using TLC:  Correlation Between Pretreatment Homocysteine Levels and Toxicity Following Chemotherapy in Cancer Patients.” Presentation to American Society of Hematology (ASH) 33rd Annual Meeting, 1991.

Tisman, G., Vu, T., Vanyo, L., Amin, J., Malkin, S.: “Methyltetrahydrofolate Depletion Causes Decreased Cellular Transport of Cobalamin.  Pure Folate Depletion May Cause Secondary Intracellular B12 Depletion.” Presentation to American Society of Hematology (ASH) 33rd Annual Meeting, 1991.

Tisman, G., Vu, T., Amin, J., Ramos, M.: “Hydroxyurea Administration Causes Decreased Levels Of Circulating Holotranscobalamin II.” Submitted for presentation to the American Society of Clinical Oncology (ASCO) May 17-19, 1992.

Tisman, G., Vu, T., Amin, J.: “Hydroxyurea Decreases Holotranscoblamin II: Possible Case of a Drug Self-Modulating Its Direct Effects On DNA Synthesis By Causing Secondary B12 Deficiency.”  Submitted for presentation to the American Association of Cancer research (AACR) 1992.

Tisman, G., Amin. J., Vu, T., Bateman, R., Luzko, G., Cordts, B., Malkin, S.: “Measurement of Red Cell B12 and HoloTCII Levels:  The Key to the Evaluation of True B12 Deficiency” Submitted for Presentation to American Society of Hematology (ASH) 34th Annual Meeting 1992.

Amin, J., Vu, T., Brenner, M., Ramos, M., Flener, V., Tisman, G.: “Chemotherapy Associated Occult Tissue Depletion of B12 in Cancer Patients, Impact on Mucosal and Hematological Toxicity.” Submitted for Presentation to American Association for Cancer Research, Inc. (AACR) 1993.

Perry Shen, Leland Foshag, Richard Essner, Glenn Tisman, Guy Gammon, Hejing Wang, Robert Elashoff, Donald Morton. “Postoperative Adjuvant Therapy Using a Polyvalent Melanoma Vaccine Improves Overall Survival of Patients with Primary Melanoma.” John Wayne Cancer Institute, Santa Monica, CA. Proceedings ASCO p 2059 1999.

Vinay M. Shah, Hanh T.H. Nguyen, Mercedita Ramos, Glenn Tisman: “The Value of Immediate Determination of C-Reactive Protein in the Hematology-Oncology Clinic.” Glenn Tisman, MD. A Medical Corporation, Whittier, CA., Blood, Vol. 104, #11, November 2004, Abstract# 3801 p 36b-37b.

Ashley S. Plant, Glenn Tisman, MD.: “Frequency of Combined Deficiencies of Vitamin D and Holotranscobalamin in Cancer Patients.” Glenn Tisman, Medical Oncology, Whittier, CA, Blood, Vol. 104, #11, November 2004, Abstract# 3674 p 4b.

Hanh T.H. Nguyen, Vinay Shah, Mercedita Ramos, Glenn Tisman, MD.: “Holotranscobalamin Deficiency and Hyperhomocysteinemia Are Common in Newly Diagnosed Cancer Patients.” Glenn Tisman, Medical Oncology, Whittier, CA, Blood Vol. 104, #11, November 2004, Abstract #3675 p 4b-5b.

ARTICLES:

Tisman, G., Herbert, V., Go, L.T. and Brenner, L. “Inhibition by Penicillamine of DNA and Protein Synthesis by Human Bone Marrow.” Pro. Soc. Exp. Biol. & Med. 139:355-363, 1972.

Herbert, V. and Tisman, G. “Effects of Deficiencies of Folic Acid and Vitamin B12 on Central Nervous System Function and Development.” In Biology and Brain Dysfunction (G.E. Gaull, Ed.) Plenum Press, New York 1:373-393, 1972.

Herbert, V. and Tisman, G. “Pinpointing Nutritional Anemias.” Consultant 12:117-119, 1972.

Tisman, G. and Herbert, V. “Studies of Effects of Cyclic Adenosine 3’, 5’ Monophosphate in Regulation of Human Hemopoiesis In Vitro.” 9:86-91, 1973.

Tisman, G. and Herbert, V. “Marked Immunosuppression with Minimal Myelosuppression by Bleomycin In Virto.” Blood XLI, 721-726, 1973.

Tisman, G., Herbert, V. and Rosenblatt, S. “Evidence that Lithium Induces Human Granulocyte Proliferation: Elevated Serum Vitamin B12 Binding Capacity In Vitro and Granulocyte Colony Proliferation In Vitro.” Brit. J. Hemat. 24:767-771, 1973.

Tisman, G. and Herbert, V. “In Vitro Myelosuppression and Immunosuppression by Ethanol.” J. Clin. Invert. 52:1410-1414, 1973

Tisman, G., Herbert, V., Go, L.T. and Brenner, L.T. “Role of Cyclic AMP in Regulation of Hemopoiesis.” In Vitro 9:86-91, 1973.

Herbert, V., Tisman, G., Go, LT. And Brenner, L.T. “The dU Suppression Test Using II25UdR to Define Biochemical Megaloblastosis.” Brit. J. Hemat. 24:713-723, 1973.

Tisman, G., Herbert, V. and Edlis, H. “Determination of Therapeutic Index of Drugs by In Vitro Sensitivity Test Using Human Host and Tumor Cell Suspensions.” Cancer Chemotherapy Rep. 57:11-19, 1973.

Herbert, V., Tisman, G., Go, L.T. and Brenner, L.T. “B12 Dependence of Cell Uptake of Serum Folate:  An Explanation for High Serum Folate and Cell Folate Depletion in B12 Deficiency.” Blood 41:465-469, 1973.

Tisman, G. “Lithium Carbonate Protection Against Drug-Induced Leukopenia in Lymphosarcoma Patients.” IRCS (Research on Cancer, Clinical Pharmacology and Therapeutics; Hematology) 2:1509, 1974.

Herbert, V. and Tisman, G. “Hematologic Effect on Alcohol,” Ann. New York Acad. Sci. 252:307-315, 1975.

Tisman, G., Wu, SG. And Safire, G.E. “Superiority of Cytoxan-Vincristine-Prednisone-Procarbazine in Treatment in Non-Hodgkins Lymphoma.” IRCS (Research on Cancer, Clinical Pharmacology and Therapeutics; Hematology) 3:318, 1975.

Tisman, G. and Herbert V. “Modulation of In Vitro Lymphocyte Stimulation by Subpopulations of Transforming Lymphocytes.” Cancer 40:2109, 1977,

Tisman G. and Wu S.G. “Hematological Effects of Lithium Therapy” Editor: Neil Johnson Publisher: D. Blommer, MTP Press, Falcon House, Lancaster, England, 1980.

Tisman, G. and Wu. S.G.: “A Seven Year Laboratory and Clinical Experience with Lithium Carbonate as an Adjuvant to Cancer Chemotherapy.  In Lithium Effects on Granulopoiesis and Immune Function.” Edited by Arthur H. Rossof and William A. Robinson.  Published: Plenum Press, New York, 1980.

Tisman, G. and Wu, S.G.: “Effectiveness of Intermediate Dose Methotrexate - High Dose 5-Fluorouracil Sequential Combination Chemotherapy in Refractory Breast Cancer and as Primary Therapy in Metastatic Adenocarcinoma of the Colon.” Cancer Treatment Report, 64:829-835, 1980.

Tisman, G.: “Predictors of Tumor Response- An In Vitro Model.” In Modern Radiation Oncology.  Harper & Row, Publishers, Philadelphia. Vol. II, Chapter 33:754-767, 1984.

Tisman, G., Tisman, N., Buck, L., Nguyen, H., Jones, M.E. and Orbon, A. “Use of a Computer Program to Analyze Tumor Markers.” International Academy of Tumor Marker Oncology.  Journal of Tumor Marker Oncology Vol. 3, No. 2, 1988.

Vanyo, L., Vu, T., Ramos, M., Amin, J., Conners, S., Bateman, R., and Tisman, G.: “Lithium Induced Perturbations of Vitamin B12, Folic Acid and DNA Metabolism.” In The International Symposium on Present Status and Perspectives of Lithium in Biology and Medicine, European Academy, Nonweiler/Trier (Germany) 1990.

Vu, T., Amin, J., Ramos, M., Flener, V., Vanyo, L. Tisman, G.: “New Assay for the Rapid Determination of Plasma Holotranscobalamin II Levels: Preliminary Evaluation in Cancer Patients” American Journal of Hematology 42:202-211, 1993.

Tisman, G., Vu, T., Amin, J., Luszko, M., Ramos, M., Flener, V., Cordts, V., Bateman R., Malkin, S., Browder, T.: “Measurement of Red Blood Cell-Vitamin B12: A Study of the Correlation Between Intracellular B12 Content and Concentrations of Plasma Holotranscobalamin II.” American Journal of Hematology 43:226-229, 1993.

Chapter in The Mount School of Medicine “Total Nutrition”;  “Nutrition and Blood Disorders” by Neville Colman, M.D. and Glenn Tisman M.D.; Edited by Victor Herbert, M.D, pp 518-529, 1995. Published by St. Martin’s.

Strum SB, McDermed JE, Scholz M.C., Johnson H & Tisman G: Anemia associated with androgen deprivation (AAAD) in prostate cancer patients receiving combination hormone blockade. Brit J Urol. June 1997

Tisman, G., MacDonald, D., Shindell, N., Reece, E., Patel, P., Honda, N., Nishimora, E., Garris, J., Shanahan, W., Chisti, N., McCarthy, J., Moaddeli, S., Sargent, D., Plant, A.: “Oxaliplatin Toxicity Masquerading as Recurrent Colon Cancer” Journal of Clinical Oncology 22:15:3202-3204, 2004

Tisman, Glenn, MD, Conn’s Current Therapy, 2005: “Pernicious Anemia and Other Megaloblastic Anemias.” P 443-448. (Chapter)

Plant, Ashley; Tisman, Glenn “Frequency of combined deficiencies ofvitamin D and holotranscobalamin in cancer patients. Nutrition and Cancer vol 56, No. 2 2007

Tisman, G, Kutik, S, Rainville, C: Coexistence of pernicious anemia and prostate cancer - 'an experiment of nature' involving vitamin B12 modulation of prostate cancer growth and metabolism: a case report Journal of Medical Case Reports 2009, 3:9295 (24 November 2009)

Fournier,  C Tisman, G Kleinman, R: Clinical evidence for overcoming capecitabine resistance in a woman with breast cancer terminating in radiologically occult micronodular pseudo-cirrhosis with portal hypertension: a case report Yong Park, William D MacDonald Journal of Medical Case Reports 2010, 4:112 (21 April 2010)

Khan and Tisman: Pica in iron deficiency: a case series, Journal of Medical Case Reports 4:862010, http://www.jmedicalcasereports.com/content/4/1/86

Tisman,  G Garcia, A Control of prostate cancer associated with withdrawal of a supplement containing folic acid, L-methyltetrahydrofolate and vitamin B12: a case report Journal of Medical Case Reports 2011, 5:413 (25 August 2011)

Book Chapter: Modulation of One-Carbon Metabolism by B Vitamins: Implications for Transformation and Progression of Prostate Cancer by Glenn Tisman the book "Prostate Cancer - From Bench to Bedside" edited by Philippe E. Spiess, ISBN 978-953-307-331-6, InTech, November 11, 2011

Book Chapter: Describing Prostate Cancer Dynamics: Second Look at PSA- Doubling Time and PSA-Specific Growth Rate in the book "Advances in Prostate Cancer" edited by Gerhard Hamilton, ISBN 978-953-51-0932-7, InTech, January 1, 2013

Tisman, G “Elevated Levels of Serum B12, Folate and Homocysteine in Patients with Regional Prostate and Breast Cancer: Homocysteine Resistance to Suppression by Folate and B12”  Manuscript Submitted to Nutrition and Metabolic Insights Publisher Libertas Academica; December 2015

Tisman, G. Khan, Y“Chemotherapy Associated Acute Suppression of Serum Holotranscobalamin: (Active B12) Manuscript Submitted to Clinical Medicine Insights: Blood Disorders Journal Publisher Libertas Academica; December 2015

SOFTWARE DEVELOPMENT (2014 programming in Apple’s XCODE/SWIFT version 7)

Method for calculating Gentamicin dosing for patients with renal compromise (Palm OS) ~ 2001

Calculating risk for breast cancer based on Gail model and other family history characteristics (Palm OS) ~2002

CancerPal: Calculates and projects tumor cell growth characteristics predicting tumor specific growth rates and tumor mass based on past growth rates (Xcode v 4.6.2, for all Apple mobile devices iOS) see http://www.healthsciencereports.com 2012. Available as download from App store. Price = $1.99.

Preliminary name: “Nibs&Mabs” Currently developing an Apple App written in SWIFT,  Apple language for Apple mobile devices, which is an Atlas and eBook translating molecular biology of tyrosine kinases, cell signaling, and an encyclopedia of investigational drugs for the practicing physician and molecular biologists A searchable handheld encyclopedia of drugs, tumor targets, and molecular targets so far contains 1400 investigational drugs and their targets and cartoons of mechanisms of action. 2016.